Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Portage Pharmaceuticals, a subsidiary of Canada-based Portage Biotech, has entered into a materials collaborative research and development agreement (M-CRADA) with the National Eye Institute, one of the National Institutes of Health.
Subscribe to our email newsletter
The company will provide its lead cell permeable peptide targeting inflammatory diseases to Dr. Robert Nussenblatt to investigate its efficacy in animal models of uveitis.
Portage will also be responsible for providing financial support for these studies.
Portage Pharmaceuticals CEO Bruce Littman said, "This agreement will enable Portage to benefit from Dr. Nussenblatt’s great depth of knowledge and experience in the area of inflammatory eye diseases while providing tools to further the understanding of the pathogenesis of these diseases and possibly a new therapeutic approach that could be a great benefit to patients."
Portage is focused in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs.
After proof of concept, the company will look to sell or license the products to large pharmaceutical companies for further development and commercialization.